Talha Badar: What is the right duration of VENETOCLAX with HMA for AML

Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:

“Weekend review:

 What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days? Brief review of literature in this thread.

VIALE-A trial recommends AZA for seven days combined with VEN for 28 days for every 28 days However in RWD it is associated with significant myelosuppression, especially high TRM in elderly patients.

Christophe Willekens from France evaluated 82 AML pts with 7+7 regimen: ASH22 m Age 75, 29% meets exclusion criteria of VIALE-A 56% sAML, 70% adverse risk, 37% PS 2-4 CR/CRi 41.5% C1, 53.9% C2 EFS 7.5 and OS 12.8 m Better who met VIALE-A criteria; EFS and OS 11.4 and 13.8 m.

Authors from Albert Einstein College of Medicine explored Weekly low dose decitabine and VEN in MDS and AML 39 pts: ORR in AML and MDS was 88% and 64% In TP53m AML, CRc 71%, mOS 10.7m Authors concluded non-cytotoxic sustained drug exposure often not possible with standard reaction.

Another study from China including 36 pts: 14 days of Ven at 100 mg OD (without azoles) + 7 days of AZA OS and PFS 17 (4–29) & 12 (1–28) mo, ORR: 69.4%, CRc 66.7% G3-4 cytopenia 25-44% less frequent then VIALE-A.

Our data on 301 patients 28 days of Ven not better than 21/14 days 14D may be suitable for favorable and 21D for adverse AML G3 or > low ANC and low Plt; 45%/48%, 39%/38, 42%/41%, among patients receiving Ven for 14, 21, and 28 D; p  NS CR/CRi were comparable between 3 gp

In conclusion, continuous Ven dosing should be avoided to prevent prolong cytopenia. Sustained drug exposure is needed for better outcome Ven dosing should be individualised based on patient and disease related features. Prospective studies are needed to better address this debate!”

Additional information.

Source: Talha Badar/X